CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators
14,662
edits
Novartis: Difference between revisions
m
Text replacement - "Reuters" to "Reuters"
m (Text replacement - "The New York Times" to "The New York Times") |
m (Text replacement - "Reuters" to "Reuters") |
||
| Line 101: | Line 101: | ||
In 2009, Novartis reached an agreement to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.<ref>{{Cite web |title=Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL® |url=https://www.worldpharmanews.com/content/view/1011/1/ |url-status=dead |archive-url=https://web.archive.org/web/20091113131854/http://www.worldpharmanews.com/content/view/1011/1/ |archive-date=13 November 2009 |access-date=29 January 2021 |website=www.worldpharmanews.com}}</ref> | In 2009, Novartis reached an agreement to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.<ref>{{Cite web |title=Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL® |url=https://www.worldpharmanews.com/content/view/1011/1/ |url-status=dead |archive-url=https://web.archive.org/web/20091113131854/http://www.worldpharmanews.com/content/view/1011/1/ |archive-date=13 November 2009 |access-date=29 January 2021 |website=www.worldpharmanews.com}}</ref> | ||
In 2010, Novartis offered to pay US$39.3 billion to fully acquire [[Alcon]], the world's largest eye-care company, including a majority stake held by Nestlé. Novartis had bought 25 percent of Alcon in 2008.<ref>{{Cite news |last=Thomasson |first=Emma |date=4 January 2010 |title=Novartis seeks to buy rest of Alcon for $39 billion |work= | In 2010, Novartis offered to pay US$39.3 billion to fully acquire [[Alcon]], the world's largest eye-care company, including a majority stake held by Nestlé. Novartis had bought 25 percent of Alcon in 2008.<ref>{{Cite news |last=Thomasson |first=Emma |date=4 January 2010 |title=Novartis seeks to buy rest of Alcon for $39 billion |work=Reuters |url=https://www.reuters.com/article/us-alcon-idUSTRE6030RK20100104 |url-status=live |access-date=2010-01-04 |archive-url=https://web.archive.org/web/20131020151234/https://www.reuters.com/article/2010/01/04/us-alcon-idUSTRE6030RK20100104 |archive-date=2013-10-20}}</ref> Novartis created a new division and called it Alcon, under which it placed its CIBA VISION subsidiary and Novartis Ophthalmics, which became the second-largest division of Novartis.<ref>Novartis Press Release. 8 April 2011 [http://www.novartis.com/newsroom/feature-stories/2011/04/stronger-together-1.shtml Stronger together: Novartis and Alcon creating the global leader in eye care] {{webarchive |url=https://web.archive.org/web/20131020094845/http://www.novartis.com/newsroom/feature-stories/2011/04/stronger-together-1.shtml |date=20 October 2013 }}</ref> The total cost for Alcon amounted to $60 billion.<ref>{{Cite web |title=Can Novartis' CEO resist going for a megamerger with cash from asset sales? - FiercePharma |url=http://www.fiercepharma.com/pharma/can-novartis-ceo-resist-going-for-a-megamerger-cash-from-asset-sales |access-date=6 February 2018 |website=www.fiercepharma.com |date=30 May 2017 |archive-date=30 October 2020 |archive-url=https://web.archive.org/web/20201030110205/https://www.fiercepharma.com/pharma/can-novartis-ceo-resist-going-for-a-megamerger-cash-from-asset-sales |url-status=live }}</ref> | ||
====2011–present==== | ====2011–present==== | ||
| Line 118: | Line 118: | ||
In November 2016, the company announced it would acquire [[Selexys Pharmaceuticals]] for $665 million.<ref>{{Cite web |date=21 November 2016 |title=Novartis Acquires Selexys Pharmaceuticals - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN |url=http://www.genengnews.com/gen-news-highlights/novartis-acquires-selexys-pharmaceuticals/81253455 |access-date=21 November 2016 |archive-date=30 October 2018 |archive-url=https://web.archive.org/web/20181030090528/https://www.genengnews.com/gen-news-highlights/novartis-acquires-selexys-pharmaceuticals/81253455 |url-status=live }}</ref> In December, the company acquired [[Encore Vision]], gaining the company's principle compound, EV06, is a first-in-class topical therapy for [[presbyopia]].<ref>{{Cite web |date=20 December 2016 |title=Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN |url=http://www.genengnews.com/gen-news-highlights/novartis-buys-encore-vision-for-presbyopia-therapy-eyedrops/81253589 |access-date=21 December 2016 |archive-date=21 December 2016 |archive-url=https://web.archive.org/web/20161221162554/http://www.genengnews.com/gen-news-highlights/novartis-buys-encore-vision-for-presbyopia-therapy-eyedrops/81253589 |url-status=live }}</ref> In December Novartis acquired Ziarco Group Limited, bolstering its presence in eczema treatments.<ref>{{Cite web |last=Terry |first=Mark |date=19 December 2016 |title=Novartis AG Snaps Up Mid-Stage Eczema Rival |url=https://www.biospace.com/article/novartis-ag-snaps-up-mid-stage-eczema-rival-/ |website=BioSpace |access-date=29 October 2018 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806004628/https://www.biospace.com/article/novartis-ag-snaps-up-mid-stage-eczema-rival-/ |url-status=live }}</ref> | In November 2016, the company announced it would acquire [[Selexys Pharmaceuticals]] for $665 million.<ref>{{Cite web |date=21 November 2016 |title=Novartis Acquires Selexys Pharmaceuticals - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN |url=http://www.genengnews.com/gen-news-highlights/novartis-acquires-selexys-pharmaceuticals/81253455 |access-date=21 November 2016 |archive-date=30 October 2018 |archive-url=https://web.archive.org/web/20181030090528/https://www.genengnews.com/gen-news-highlights/novartis-acquires-selexys-pharmaceuticals/81253455 |url-status=live }}</ref> In December, the company acquired [[Encore Vision]], gaining the company's principle compound, EV06, is a first-in-class topical therapy for [[presbyopia]].<ref>{{Cite web |date=20 December 2016 |title=Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN |url=http://www.genengnews.com/gen-news-highlights/novartis-buys-encore-vision-for-presbyopia-therapy-eyedrops/81253589 |access-date=21 December 2016 |archive-date=21 December 2016 |archive-url=https://web.archive.org/web/20161221162554/http://www.genengnews.com/gen-news-highlights/novartis-buys-encore-vision-for-presbyopia-therapy-eyedrops/81253589 |url-status=live }}</ref> In December Novartis acquired Ziarco Group Limited, bolstering its presence in eczema treatments.<ref>{{Cite web |last=Terry |first=Mark |date=19 December 2016 |title=Novartis AG Snaps Up Mid-Stage Eczema Rival |url=https://www.biospace.com/article/novartis-ag-snaps-up-mid-stage-eczema-rival-/ |website=BioSpace |access-date=29 October 2018 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806004628/https://www.biospace.com/article/novartis-ag-snaps-up-mid-stage-eczema-rival-/ |url-status=live }}</ref> | ||
In late October 2017, '' | In late October 2017, ''Reuters'' announced that Novartis would acquire [[Advanced Accelerator Applications]] for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.<ref>{{Cite news |author=John Miller |date=3 November 2017 |title=Novartis to buy French cancer specialist AAA for $3.9 billion |work=Reuters |url=https://www.reuters.com/article/us-novartis-advanced-accelerator/novartis-to-buy-french-cancer-specialist-aaa-for-3-9-billion-idUSKBN1CZ0HC/ |access-date=17 December 2023}}</ref> | ||
In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novartis to acquire Novartis' 36.5 percent stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).<ref>{{Cite web |date=27 March 2018 |title=GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business {{!}} GSK |url=https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ |website=www.gsk.com |access-date=27 March 2018 |archive-date=27 November 2020 |archive-url=https://web.archive.org/web/20201127035152/https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ |url-status=live }}</ref><ref name=":1">{{Cite news |date=2018-03-27 |title=GSK buys out Novartis in $13 billion consumer healthcare shake-up |work=Reuters |url=https://uk.reuters.com/article/uk-novartis-gsk-idUKKBN1H30FM |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805204401/https://uk.reuters.com/article/uk-novartis-gsk-idUKKBN1H30FM |url-status=dead }}</ref> In April of the same year, the business utilised some of the proceeds from the aforementioned GlaxoSmithKline deal to acquire [[Avexis]] for $218 per share or $8.7 billion in total, gaining the lead compound [[AVXS-101]] used to treat [[spinal muscular atrophy]].<ref>{{Cite news |date=2018-04-09 |title=Novartis bets big on gene therapy with $8.7 billion AveXis deal |work=Reuters |url=https://uk.reuters.com/article/uk-novartis-avexis-idUKKBN1HG0FP |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805202937/https://uk.reuters.com/article/uk-novartis-avexis-idUKKBN1HG0FP |url-status=dead }}</ref> In August 2018, Novartis signed a deal with Laekna-a Shanghai-based pharmaceutical company for its two clinical-stage cancer drugs.<ref>{{Cite web |title=Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech {{!}} FierceBiotech |url=https://www.fiercebiotech.com/biotech/novartis-licenses-out-unwanted-gsk-cancer-meds-to-chinese-biotech |access-date=2018-08-03 |website=www.fiercebiotech.com |date=August 2018 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805145648/https://www.fiercebiotech.com/biotech/novartis-licenses-out-unwanted-gsk-cancer-meds-to-chinese-biotech |url-status=live }}</ref> Novartis gave Laekna the exclusive international rights for the drugs that are oral pan-Akt [[kinase inhibitor]]s namely; afuresertib (ASB138) and uprosertib (UPB795).<ref>{{Cite news |title=China's Laekna Inks Two-Drug Deal with Novartis {{!}} BioSpace |work=BioSpace |url=https://www.biospace.com/article/china-s-laekna-inks-two-drug-deal-with-novartis/ |access-date=2018-08-03 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805174528/https://www.biospace.com/article/china-s-laekna-inks-two-drug-deal-with-novartis/ |url-status=live }}</ref> In mid-October, the company announced it would acquire [[Endocyte]] Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.<ref>{{Cite news |date=2018-10-18 |title=Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash |work=Reuters |url=https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805233223/https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |url-status=dead }}</ref><ref>{{Cite news |date=2018-10-18 |title=Novartis pushes deeper into nuclear medicine with $2.1 billion deal |work=Reuters |url=https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805190743/https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |url-status=dead }}</ref> Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate [[Lutetium (177Lu) vipivotide tetraxetan|<sup>177</sup>Lu-PSMA-617]] being targeted against metastatic castration-resistant prostate cancer.<ref>{{Cite web |date=18 October 2018 |title=Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms |url=https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms |website=Novartis |access-date=18 October 2018 |archive-date=25 November 2020 |archive-url=https://web.archive.org/web/20201125145132/https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms |url-status=live }}</ref> In late December the company announced it would acquire France-based contract manufacturer, CellforCure from [[LFB]], boosting its capacity to produce cell and gene therapies.<ref>{{Cite news |date=20 December 2018 |title=Novartis to buy France's CellforCure to boost cell, gene therapy |work=Reuters |url=https://uk.reuters.com/article/us-novartis-cellforcure/novartis-to-buy-frances-cellforcure-to-boost-cell-gene-therapy-idUKKCN1OJ287 |access-date=20 December 2018 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806011641/https://uk.reuters.com/article/us-novartis-cellforcure/novartis-to-buy-frances-cellforcure-to-boost-cell-gene-therapy-idUKKCN1OJ287 |url-status=dead }}</ref> | In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novartis to acquire Novartis' 36.5 percent stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).<ref>{{Cite web |date=27 March 2018 |title=GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business {{!}} GSK |url=https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ |website=www.gsk.com |access-date=27 March 2018 |archive-date=27 November 2020 |archive-url=https://web.archive.org/web/20201127035152/https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ |url-status=live }}</ref><ref name=":1">{{Cite news |date=2018-03-27 |title=GSK buys out Novartis in $13 billion consumer healthcare shake-up |work=Reuters |url=https://uk.reuters.com/article/uk-novartis-gsk-idUKKBN1H30FM |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805204401/https://uk.reuters.com/article/uk-novartis-gsk-idUKKBN1H30FM |url-status=dead }}</ref> In April of the same year, the business utilised some of the proceeds from the aforementioned GlaxoSmithKline deal to acquire [[Avexis]] for $218 per share or $8.7 billion in total, gaining the lead compound [[AVXS-101]] used to treat [[spinal muscular atrophy]].<ref>{{Cite news |date=2018-04-09 |title=Novartis bets big on gene therapy with $8.7 billion AveXis deal |work=Reuters |url=https://uk.reuters.com/article/uk-novartis-avexis-idUKKBN1HG0FP |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805202937/https://uk.reuters.com/article/uk-novartis-avexis-idUKKBN1HG0FP |url-status=dead }}</ref> In August 2018, Novartis signed a deal with Laekna-a Shanghai-based pharmaceutical company for its two clinical-stage cancer drugs.<ref>{{Cite web |title=Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech {{!}} FierceBiotech |url=https://www.fiercebiotech.com/biotech/novartis-licenses-out-unwanted-gsk-cancer-meds-to-chinese-biotech |access-date=2018-08-03 |website=www.fiercebiotech.com |date=August 2018 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805145648/https://www.fiercebiotech.com/biotech/novartis-licenses-out-unwanted-gsk-cancer-meds-to-chinese-biotech |url-status=live }}</ref> Novartis gave Laekna the exclusive international rights for the drugs that are oral pan-Akt [[kinase inhibitor]]s namely; afuresertib (ASB138) and uprosertib (UPB795).<ref>{{Cite news |title=China's Laekna Inks Two-Drug Deal with Novartis {{!}} BioSpace |work=BioSpace |url=https://www.biospace.com/article/china-s-laekna-inks-two-drug-deal-with-novartis/ |access-date=2018-08-03 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805174528/https://www.biospace.com/article/china-s-laekna-inks-two-drug-deal-with-novartis/ |url-status=live }}</ref> In mid-October, the company announced it would acquire [[Endocyte]] Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.<ref>{{Cite news |date=2018-10-18 |title=Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash |work=Reuters |url=https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805233223/https://uk.reuters.com/article/us-endocyte-m-a-novartis-idUKKCN1MS0JZ |url-status=dead }}</ref><ref>{{Cite news |date=2018-10-18 |title=Novartis pushes deeper into nuclear medicine with $2.1 billion deal |work=Reuters |url=https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |access-date=9 January 2019 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805190743/https://uk.reuters.com/article/uk-endocyte-m-a-novartis-idUKKCN1MS0PN |url-status=dead }}</ref> Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate [[Lutetium (177Lu) vipivotide tetraxetan|<sup>177</sup>Lu-PSMA-617]] being targeted against metastatic castration-resistant prostate cancer.<ref>{{Cite web |date=18 October 2018 |title=Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms |url=https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms |website=Novartis |access-date=18 October 2018 |archive-date=25 November 2020 |archive-url=https://web.archive.org/web/20201125145132/https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms |url-status=live }}</ref> In late December the company announced it would acquire France-based contract manufacturer, CellforCure from [[LFB]], boosting its capacity to produce cell and gene therapies.<ref>{{Cite news |date=20 December 2018 |title=Novartis to buy France's CellforCure to boost cell, gene therapy |work=Reuters |url=https://uk.reuters.com/article/us-novartis-cellforcure/novartis-to-buy-frances-cellforcure-to-boost-cell-gene-therapy-idUKKCN1OJ287 |access-date=20 December 2018 |archive-date=6 August 2020 |archive-url=https://web.archive.org/web/20200806011641/https://uk.reuters.com/article/us-novartis-cellforcure/novartis-to-buy-frances-cellforcure-to-boost-cell-gene-therapy-idUKKCN1OJ287 |url-status=dead }}</ref> | ||